2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1853

Klf5+/-;Fli1+/- Mice Recapitulate Protracted Wound Healing and Cardiac and Intestinal Involvement Associated with Systemic Sclerosis
Abstract Number: 292

Knee Osteoarthritis and the Risk of Fall Injuries Among Older Adults: The Health ABC Study
Abstract Number: 296

Knee Osteoarthritis As Risk for Hip Osteoarthritis
Abstract Number: 2135

Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation
Abstract Number: 1254

Knee Pain and Patient Preference for Knee Replacement: Healthcare Access Matters
Abstract Number: 303

Knee Physical Exam Findings and Self-Reported Symptoms Are Associated with MRI-Detected Effusion-Synovitis Among Participants with or at Risk for Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
Abstract Number: 1952

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis
Abstract Number: 2854

Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern
Abstract Number: 894

Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Abstract Number: 2634

Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis
Abstract Number: 1183

Lack of Awareness of Sexual Health in Rheumatology. High Prevalence of Sexual Dysfunction Among Women with Rheumatic Diseases
Abstract Number: 1608

Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis
Abstract Number: 2264

Lack of Obesity-Related Changes in Adipocytes and Inflammatory Cells in the Infrapatellar Fat Pad (IFP): A Different Type of Fat?
Abstract Number: 2824

Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Abstract Number: 2147

Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].